Beach Investment Counsel Inc. PA Cuts Holdings in Roche Holding AG (OTCMKTS:RHHBY)

Beach Investment Counsel Inc. PA decreased its holdings in Roche Holding AG (OTCMKTS:RHHBY) by 6.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 53,910 shares of the company’s stock after selling 3,650 shares during the quarter. Beach Investment Counsel Inc. PA’s holdings in Roche were worth $2,218,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of RHHBY. Altrius Capital Management Inc increased its holdings in shares of Roche by 0.3% in the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company’s stock valued at $6,399,000 after acquiring an additional 603 shares during the period. SVB Wealth LLC bought a new stake in Roche during the fourth quarter valued at about $555,000. HighPoint Advisor Group LLC grew its stake in Roche by 2.8% in the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock valued at $387,000 after purchasing an additional 304 shares during the last quarter. Hancock Whitney Corp raised its holdings in Roche by 6.8% in the fourth quarter. Hancock Whitney Corp now owns 23,516 shares of the company’s stock worth $820,000 after purchasing an additional 1,496 shares in the last quarter. Finally, Minot DeBlois Advisors LLC purchased a new stake in shares of Roche during the fourth quarter valued at about $752,000.

Wall Street Analysts Forecast Growth

RHHBY has been the topic of a number of analyst reports. HSBC downgraded shares of Roche from a “buy” rating to a “hold” rating in a research report on Monday, April 28th. Morgan Stanley began coverage on shares of Roche in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. UBS Group upgraded Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, Hsbc Global Res downgraded Roche from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Roche presently has a consensus rating of “Moderate Buy”.

Roche Stock Performance

RHHBY opened at $40.86 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. The firm’s 50-day moving average price is $39.14 and its 200-day moving average price is $38.86. Roche Holding AG has a 52-week low of $33.30 and a 52-week high of $44.31.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.